Puma Biotech (PBYI) Misses Q1 EPS by 4c, provides guidance

Puma Biotech (NASDAQ: PBYI) reported Q1 EPS of ($0.04), $0.04 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $44.8 million versus the consensus estimate of $49 million.

GUIDANCE:

Puma Biotech sees Q2 2026 revenue of $52-55 million, versus the consensus of $52 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• Goldman Sachs (GS) Tops Q2 EPS by $6.60, Beats on Revenue
• Kodiak Gas Services Inc (KGS) PT Raised to $90 at Stifel on Multi-Year Growth Potential
• Chatham Lodging Trust (CLDT) PT Raised to $14 at Stifel on Updated Estimates